Regeneron Seeks FDA Approval of VEGF Trap-Eye for Wet AMD

As expected, Regeneron Pharmaceuticals Inc. submitted a biologics license application (BLA) to the FDA for its VEGF Trap-Eye (aflibercept ophthalmic solution) to treat the neovascular form of age-related macular degeneration (wet AMD). Regeneron's submission includes a request for priority PDUFA review.